TABLE 3.
Clinical, laboratory, and imaging features of COVID‐19 in patients with GBS
| ADIP | AMSAN | AMAN | Mixed | NA | All GBS | |
|---|---|---|---|---|---|---|
| References | [36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75] | [57, 67, 76, 77, 78, 79, 98] | [67, 80, 81, 82, 97] | [83, 84, 85] | [65, 71, 82, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96] | [36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97] |
| No. of patients % (n/total) | 59.8 (55/92) | 13.0 (12/92) | 5.4 (5/92) | 3.3 (3/92) | 18.5 (17/92) | 100 (92/92) |
| COVID‐19 RT PCR % (n) | ||||||
| Positive | 81.8 (45) | 90.9 (10) | 100.0 (4) | 100.0 (2) | 100.0 (14) | 88.2 (75) |
| Negative | 18.2 (10) | 9.1 (1) | 0 | 0 | 0 | 11.8 (11) |
| COVID‐19 serology % (n) | ||||||
| +IGG | 16.4 (9) | 16.7 (2) | 0 | 0 | 0 | 12 (11) |
| +IGM | 0 | 0 | 0 | 0 | 0 | 0 |
| +IGG & +IGM | 1.8 (1) | 0 | 20 (1) | 0 | 0 | 2.2 (2) |
| −IGG or −IGM | 3.6 (2) (IgM) | 0 | 0 | 0 | 0 | 2.2 (2) |
| NA | 81.8 (45) | 83.3 (10) | 80 (4) | 100 (3) | 100 (17) | 85.9 (79) |
| Chest imaging % (n) | ||||||
| Positive | 60 (33) | 75 (9) | 20 (1) | 33.3 (1) | 23.5 (4) | 52.2 (48) |
| Negative | 16.4 (9) | 16.7 (2) | 20 (1) | 33.3 (1) | 11.8 (2) | 16.3 (15) |
| NA | 23.6 (13) | 8.3 (1) | 60 (3) | 33.3 (1) | 64.7 (11) | 31.5 (29) |
| COVID‐19 symptoms % (n) | ||||||
| Fever | 58.5 (31) | 63.6.0 (7) | 80.0 (4) | 66.7 (2) | 75.0 (12) | 64.3 (56) |
| Dyspnea | 22.6 (12) | 45.5 (5) | 20.0 (1) | 66.7 (2) | 12.5 (2) | 25.3 (22) |
| Cough | 67.9 (36) | 81.8 (9) | 40.0 (2) | 66.7 (2) | 56.3 (9) | 66.7 (58)+ |
| Headache | 17.0 (9) | 0 | 20.0 (1) | 33.3 (1) | 6.3 (1) | 13.8 (12) |
| Other UR symptoms | 13.2 (7) | 9.1 (1) | (1) | 0 | 18.8 (3) | 13.8 (12) |
| Myalgia | 17.0 (9) | 9.1 (1) | 0 | 0 | 18.8 (3) | 14.9 (13) |
| Anosmia and/or ageusia | 32.1 (17) | 18.2 (2) | 0 | 0 | 25.0 (4) | 26.4 (23) |
| GI | 20.8 (11) | 0 | 20.0 (1) | 33.3 (1) | 25.0 (4) | 19.5 (17) |
| Other symptoms | 7.5 (4) | 0 | 0 | 0 | 0 | 4.6 (4) |
| Asymptomatic | 5.7 (3) | 0 | 0 | 0 | 0 | 3.4 (3) |
| COVID‐19 labs % (n) | ||||||
| Inflammatory markers | 62.5 (25) | 77.7 (7) | 50.0 (1) | 0 | 45.5 (5) | 59.4 (38) |
| Lymphocytopenia | 32.5 (13) | 66.7 (6) | 50.0 (1) | 50.0 (1) | 217.3 (3) | 37.5 (24) |
| Normal | 20.0 (8) | 0 | 50.0 (1) | 50.0 (1) | 45.5 (5) | 23.4 (15) |
| COVID‐19 ARDS % (n) | ||||||
| Yes | 11.1 (6) | 18.2 (2) | 0 | 0 | 5.9 (1) | 9.1 (9) |
| No | 88.9 (48) | 81.8 (9) | 100 (4) | 100 (3) | 94.1 (16) | 90.9 (80) |
| COVID‐19 therapy % (n) | ||||||
| Steroids | 14.3 (7) | 16.7 (2) | 25.0 (1) | 0 | 6.7 (1) | 13.2 (11) |
| Remdesevir | 0 | 16.7 (2) | 0 | 0 | 0 | 2.4 (2) |
| Other antivirals | 36.7 (18) | 50.0 (6) | 0 | 0 | 20.0 (3) | 32.5 (27) |
| Hydroxicloriquine | 40.8 (20) | 58.3 (7) | 25.0 (1) | 33.3 (1) | 46.7 (7) | 43.4 (36) |
| Antibiotics | 16.3 (8) | 33.3 (4) | 50.0 (2) | 0 | 13.3 (2) | 19.3 (16) |
| None | 46.9 (23) | 16.7 (2) | 25.0 (2) | 66.7 (2) | 33.3 (5) | 40.9 (34) |
| COVID‐19 outcome % (n) | ||||||
| Symptomatic | 24.2 (8) | 14.3 (1) | 250. (1) | 66.7 (2) | 0 | 20.7 (12) |
| Asymptomatic | 72.7 (24) | 71.4 (5) | 75.0 (3) | 33.3 (1) | 100 (11) | 75.6 (44) |
| Death | 3.0 (1) | 14.3 (1) | 0 | 0 | 0 | 3.4 (2) |
Note: Percentages are observed cases/cases where the information is available, unless otherwise reported.
Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMSAN, acute motor sensory axonal neuropathy; GBS, Guillain‐Barré syndrome; GI, gastrointestinal; UR, upper respiratory.